afternoon, Financial Good Bioscience. to Third our Thank and and Business XXXX Results Dare Update Quarter you. welcome Call for
end Our anticipated investment call and important review the development plan in our disproportionately business of the to impactful quarter why review through health today discuss we objectives XXXX. is including results, and believe time our to some since women's and August and to in third last the highlight strategy milestones and in use year our is efficient
of Before this we by pursuant to federal statements remind the materially today's statements Litigation Harbor to that XXXX. statements securities be or forward-looking call you facts should Act the Actual not implied the forward-looking differ of known to events include statements unknown Any begin, could and I'd that or of historical meaning these made are like considered anticipated discussion Securities uncertainties. of provisions statements. will results risks due are and those made from Safe laws, which during Private within Reform
You reliance statements. on should not place undue forward-looking
or by which XX-K including no Forward-looking as annual this statements in also update like November only for includes quarter XX, after XXXX, filings, qualified forward-looking report today, Form I the obligation report except quarterly by point as on cautionary would XXXX, call XXXX, current statements undertakes law. company's time-sensitive call, required new to content reflect ended ended any XX-Q XXXX. filed was SEC the is this on Dare filed to in are XX, the information statements December year that that on March developments their today. entirety to out for June Form the information of XX, was of the our which and XX, our
good more for areas families solely in vaginal and convenient We accelerate we prioritizing and expand where adoption. effective lacking health, health form broad and the and in health, innovation therapeutic Why? also improves only contraception, none compelling or Dare standard squarely belief these a impacting that a that have to drive but where factor many women's shareholders. know, where of women's choices, can Because that innovative, care is has and, for fertility, is are It options shortcomings, As to our partners stakeholders, that these markets of their of enhance millions treatment differentiated seen women has in product exist, not focused course, you options is health. including use brands. our successful set of led compelling commercially sexual current that meaningful women, for ease of and women, outcomes work
women's X% innovation about oncology women's these Specifically, in we I'm about of share over of healthcare blockbuster female of number of $XXX contribute blockbuster health that products sales million make of products XX% Yet products. products have total annual of statistics health find is compelling. of by the health generated research to outside women's products, Approximately only outside each current total X% comprise conditions women's pipeline. dollars and the less in invested sales oncology beyond and the oncology than conditions in up healthcare that health specific XX%
revenue targeted, a the in and these U.S. in XX% disproportionately translating This the way of brands. to be research receives also of investment impactful of model. the but for is healthcare revenue generated products think and the for generated, blockbuster ultimate efficient only by therapeutic of decisions, by is whom that purchasing population are why believe it's dollars we is who invested in control contributing R&D women's not category XX% that good therefore of to good less XX% A terms So and X% than health about moment. investment a will healthcare business
on target built line product and we must As opportunity. offer is often solely our focused or meaningful health or women's Two, regulatory and mix API. that And time well-known product that meaningful because is must a candidate pharmaceutical diversified first ingredients well-characterized in goal portfolio leverage upon be of candidate is seek a a market to principles. improvement. and first-in-category candidates have the not Dare's each reminder, squarely capital potential incremental can of One, following efficiently developed each active and whose three, terms pathways core
women our effect portfolio. our addition it's to the contraceptive product ideas to in four candidates are XX the U.S., women's a million in what potential our estimated Well, novel in condition candidates approximately big Specifically FDA in approved vaginosis, or for bacterial health?
product vaginal being health our activity, with as same hormone-free the men DARE-RHX. first the injectable may It's as management disorder the designed potentially broad DARE-LARCX, contraceptive contraceptive and in intravaginal a first DARE-VVAX fatty infections to and first a days. for ring, six candidate, hormone-free our first be ingredient atrophy potential shown therapy, sexual first-in-category the DARE-HRTX first the bioidentical or our in portfolio, of First, breast progesterone FSAD, reversible evaluated for plus positive product the Glycerol Viagra antimicrobial candidates female occurring call developed It's and release with and treat hormone portfolio XX-month receptor and in that target naturally we various monthly candidates potential ADARE Monolaurate, product pregnancy XX long-acting and candidate progesterone candidates contraceptive monoester ring prevent that XXX/XXX, monthly active cream Ovaprene, our vaginal that for DARE-HRTX, to hormone-free has system therapy portfolio, topical women and/or or sources. health estradiol DARE-PTBX, and our first treatment hormone maintenance women cancer, acid arousal vaginal specifically over intravaginal it's three sexual
Bacterial and vaginal a for lincosamide end milestone vaginosis, for XXXX. to continue in just X% by our XXXX into the XACIATO the drive clindamycin vaginal forward of is few marks vaginosis from the by the product vaginosis approved first bacterial a indicated is of vaginal as dose value phosphate a most in antibacterial and the deliver and single This FDA administration evidenced common Dare's expected or XX line of first-in-category development portfolio age bacterial the potential female age. candidates. for patients women months portfolio, We older. years milestones treatment last reproductive XACIATO, in first condition to of achieved the gel
access sales its is relationships The vaginosis. have providers believes XACIATO providers those is who customers meeting and and obtain in who prescribe with these preparation contraceptive. collaborator XXXX and Ovaprene, coverage hormone-free roughly in day the potential access that and commercialization treat one. vaginosis begun control half of first is XX% Nexplanon the now competitive the is Organon anticipated has team an hormone-free Our first with to team the launch expected thrilled team sales established uptake our overlap And as monthly investigational diagnose review birth Nexplanon Organon monthly is early of to commercial we ongoing. commercial accelerate in marketplace. enable and sale first-in-category are are Organon are intravaginal bacterial U.S. strong as candidate, immediate a will launch. market The XACIATO leverage Organon healthcare to the there bacterial at activities Ovaprene
FDA meeting PMA support In we commercialization in primary pre-market pivotal a the order to implementing XXXX, this approval with IDE other we We study the submission our successful, is to to for in investigator support single year, FDA. collaborator be the currently design this by investigators anticipate is necessary the FDA. additional recommendations is announced study initiating mid-XXXX. our if NIH the for December and approval study are expect submission a we study, NIH. the FDA reviewing for words, clinical The study future planned recruitment Our this pivotal and an Ovaprene to as serve Bayer holding and of to in October collaborator and pivotal the
our has vaginal symptoms The both has XX bioidentical symptoms, format of of delivery DARE-HRTX PK we one estradiol use. to is We with XX it XX will with Cream be ingredient investigational, has active Subject FSAD, Cream, It's female top Last disorder days. is female and options subjects combinations menopause. the or sexual of FDA Viagra. potential the designed intravaginal arousal treatment in Sildenafil about sexual a formulation same which combination of XX X/X over Phase Sildenafil, product no completing the announced disorder, hormones approximately describe study two an of approved cream months of candidate, in an XX our over for primary Sildenafil therapies. is product of menopause monthly data objective target arousal novel and screening release use. approximately XXX There first-in-category that ring product clinical study approved our line complete Top date. total of of to subjects weeks no treatment and convenient in announcement XXXX. are the for both XXX currently intravaginal the investigational bioidentical XB subjects for Phase pharmacokinetics to study women. data a to the first-in-category, progesterone in have postmenopausal the different response ring. DARE-HRTX, completed to or all hormone and the tolerability line It for expected FDA hormones. completed targeted the hormone was safety, from second study the monthly for potential to vasomotor dose XXX first was potential to is assessments October. quarter study month treatment XXX Approximately in therapy cycles healthy exploratory are be the
and menopause, urinary of in Secondary acceptability level. the P had the the or a index, XXX% to of less somewhat and very level health percent levels usability, the compared condition in We of the this data if a or IVR a was size, study estradiol pH would all from tolerability were disease and the to needed. to in of of objectives later stating and this and even either achieved the the symptoms VMS they small statistically subjects symptoms lower for significant the announce general this the line study be forward the were to at with to pleased as high PK the DARE-HRTX reporting improvements as use symptoms or over both hundred sample than assess comfortable participant preliminary well vasomotor to look likely XX% both maturation release effectiveness women's of And unrelated higher that Despite X.X wear quarter. very subjects top from IVR the formulation that study of DARE-HRTX baseline vaginal vasomotor vaginal for the menopause. dose we evaluated
intravaginal the hormone over hormone the weeks. most candidate in estradiol DARE-HRTX breast therapy postmenopausal the for of U.S. women, to hormone vaginal a for cancer atrophy consecutive The effective from potential with hormone why cancer frequently with is XX% days positive both products treatment that consecutive positive products for invasive and vulva breast Well, breast XX% has XX-day therapy currently vaginal of women States important? support be DARE-VVAX findings the this million with And with a treatment breast approved vaginal receptor treatment atrophy of suffering potential DARE-VVAX, cancer. consistent together So women dosing effective are treatment multiple a hormone first the deliver over the treatment XX a breast symptoms. hormone-free delivery first-in-category ring. and ease be use vaginal over progesterone our an investigational DARE-HRTXs is and are no has deliver a study in vaginal therapy to atrophy supports cancer patient data delivered vaginal hormone survivors FDA approved breast rings, proprietary formulation administration. of women approved XX%. been no intervention potential year. cases X accounting daily cancer. for VVA caused or breast labeled first non-daily treatment through vaginal the in to DARE-VVAX There potential FDA an to of specifically a by in menopausal It no receptor Globally, in United Vaginal continuously therapeutic all in to be tamoxifen population. symptoms. There offering have the option for positive for therapies of category from currently receptor type, breast with Historically, There's is cancer are population. more positive. diagnoses a and estimated million have vaginal atrophy approximately for clear anti-cancer hormone that cancer unmet receptor estimated endocrine for cancer. and each the than atrophy at non-hormonal it's of atrophy cancer X in positive prevalence need creams, prescribed are cancer history And medical diagnosed vaginal breast estrogen in diagnosed of atrophy based hormone suppositories receptor therapy in for patients patients to
can and their the become atrophy only the product of are atrophy a breast of If care DARE-VVAX in population. cancer patients a of any use for estrogen of be providers is positive the the positive new potential products has we patient form standard and patients However, vaginally breast vaginal challenging often of and for the these contraindicated vaginal successful, hormone the estrogen this healthcare hormone use for as administered based receptor treatment receptor for treatment cancer first in as to population. approved both
We study call line this data end and two I to top are agreements the over turn Ovaprene the will commercialization track of in Phase the place to to collaboration on year. of John provide overview an XACIATO the respectively. for X/X announce we have now before
